US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

Articles published by Arcturus Therapeutics Holdings Inc.

< Previous 1 2 3 4 Next >
News headline image
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics to Attend Upcoming Investor Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics to Attend Upcoming Investor Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics to Attend Upcoming Investor Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics to Attend Upcoming Investor Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics to Attend Upcoming Investor Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics to Attend Upcoming Investor Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
< Previous 1 2 3 4 Next >